阿尼鲁单抗联合标准治疗与真实世界外部对照相比减少成人系统性红斑狼疮患者的器官损伤累积
在TULIP试验中启动300 mg阿尼鲁单抗治疗的354例中重度活动性SLE患者与来自多伦多大学狼疮诊所队列的561例仅接受标准治疗的真实世界外部对照进行比较,采用倾向评分和删失加权校正基线混杂和失访。第208周时阿尼鲁单抗组SDI平均变化较真实世界标准治疗组低0.416分(95%CI:-0.582,-0.249;P<.001),首次SDI升高风险降低59.9%(HR:0.401;95%CI:0.213,0.753,P=.005)。
要点
- 第208周SDI平均变化:阿尼鲁单抗组较真实世界标准治疗组低0.416分(95%CI:-0.582,-0.249;P<.001)。
- 208周内SDI升高风险:阿尼鲁单抗组较真实世界标准治疗组降低59.9%(HR:0.401;95%CI:0.213,0.753,P=.005)。
- 阿尼鲁单抗组354例,真实世界标准治疗组561例,经倾向评分和删失加权校正。
核心结论
- 接受阿尼鲁单抗治疗的患者在208周后累积的器官损伤显著少于接受真实世界标准治疗的患者。
- 在标准治疗基础上加用阿尼鲁单抗可有效预防和/或延迟中重度活动性SLE患者的器官损伤。
研究设计与样本
- 阿尼鲁单抗组为TULIP试验中启动300 mg阿尼鲁单抗治疗的354例患者,真实世界标准治疗组为应用关键入选标准从多伦多大学狼疮诊所队列中筛选的561例仅接受标准治疗的患者。
- 采用倾向评分和删失加权校正基线混杂和失访。
- 主要终点为基线至第208周SDI评分变化,次要终点为首次SDI评分升高的时间。
主要发现
- 加权后,阿尼鲁单抗组SDI平均变化较真实世界标准治疗组低0.416分(95%CI:-0.582,-0.249;P<.001)。
- 阿尼鲁单抗组患者在208周内发生SDI升高的可能性较真实世界标准治疗组低59.9%(HR:0.401;95%CI:0.213,0.753,P=.005)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: Anifrolumab is approved for the treatment of systemic lupus erythematosus (SLE). We aimed to determine if anifrolumab plus standard of care (SOC) was associated with reduced organ damage accumulation in adult patients with moderately to severely active SLE compared to real-world (RW) external controls from the University of Toronto Lupus Clinic (UTLC) cohort who received SOC only. METHODS: Patients who initiated 300 mg anifrolumab in the TULIP (Treatment of Uncontrolled Lupus via the Interferon Pathway) trials were included in the anifrolumab arm; key eligibility criteria were applied to the UTLC to create the RW SOC arm. Propensity score and censoring weighting were used to account for baseline confounding and loss to follow-up. The primary endpoint was change in Systemic Lupus International Collaborating Clinics/American College of Rheumatology Damage Index (SDI) score from baseline to week 208, and the secondary endpoint was time to first SDI score increase. RESULTS: 354 patients were included in the anifrolumab arm, and 561 patients were included in the RW SOC arm. Following weighting, mean change in SDI was 0.416 points lower (95% CI: -0.582, -0.249; P < .001) in the anifrolumab arm than in the RW SOC arm. Patients in the anifrolumab arm were 59.9% less likely (hazard ratio: 0.401; 95% CI: 0.213, 0.753, P = .005) to experience an increase in SDI within 208 weeks. CONCLUSIONS: Patients who received anifrolumab accumulated significantly less organ damage after 208 weeks than patients who received RW SOC. The addition of anifrolumab to SOC is effective at preventing and/or delaying organ damage in patients with moderately to severely active SLE.
引用
- Touma Z, Bruce IN, Furie R, et al. Reduced organ damage accumulation in adult patients with SLE on anifrolumab plus standard of care compared to real-world external controls. Ann Rheum Dis. 2025. PMID: 39894690. doi:10.1016/j.ard.2025.01.025
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。